These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 7755503)

  • 1. A recombinant vaccine for Lyme disease.
    Wallich R; Kramer MD; Simon MM
    Behring Inst Mitt; 1994 Dec; (95):106-8. PubMed ID: 7755503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease.
    Wallich R; Siebers A; Jahraus O; Brenner C; Stehle T; Simon MM
    Infect Immun; 2001 Apr; 69(4):2130-6. PubMed ID: 11254567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The outer surface protein A (OspA) of Borrelia burgdorferi: a vaccine candidate and bioactive mediator.
    Kramer MD; Wallich R; Simon MM
    Infection; 1996; 24(2):190-4. PubMed ID: 8740121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group.
    Steere AC; Sikand VK; Meurice F; Parenti DL; Fikrig E; Schoen RT; Nowakowski J; Schmid CH; Laukamp S; Buscarino C; Krause DS
    N Engl J Med; 1998 Jul; 339(4):209-15. PubMed ID: 9673298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inability of truncated recombinant Osp A proteins to elicit protective immunity to Borrelia burgdorferi in mice.
    Bockenstedt LK; Fikrig E; Barthold SW; Kantor FS; Flavell RA
    J Immunol; 1993 Jul; 151(2):900-6. PubMed ID: 8335917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T helper cell priming of mice to Borrelia burgdorferi OspA leads to induction of protective antibodies following experimental but not tick-borne infection.
    Zhong W; Gern L; Kramer M; Wallich R; Simon MM
    Eur J Immunol; 1997 Nov; 27(11):2942-7. PubMed ID: 9394822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A lyme disease vaccination.
    Molloy PJ; Berardi VP; Persing DH; Sigal LH
    Clin Infect Dis; 2000 Jul; 31(1):42-7. PubMed ID: 10913394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new approach to a Lyme disease vaccine.
    Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ
    Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine Lyme borreliosis: route of inoculation determines immune response and infectivity.
    Pachner AR; Delaney E; Ricalton NS
    Reg Immunol; 1992; 4(6):345-51. PubMed ID: 1297405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2-5 years old.
    Beran J; De Clercq N; Dieussaert I; Van Hoecke C
    Clin Infect Dis; 2000 Dec; 31(6):1504-7. PubMed ID: 11096024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The recombinant outer surface protein A (lipOspA) of Borrelia burgdorferi: a Lyme disease vaccine.
    Wallich R; Kramer MD; Simon MM
    Infection; 1996; 24(5):396-7. PubMed ID: 8923055
    [No Abstract]   [Full Text] [Related]  

  • 12. Protective immunity elicited by rBCG vaccines.
    Stover CK; Bansal GP; Langerman S; Hanson MS
    Dev Biol Stand; 1994; 82():163-70. PubMed ID: 7958471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a Borrelia burgdorferi OspA T cell epitope that promotes anti-OspA IgG in mice.
    Bockenstedt LK; Fikrig E; Barthold SW; Flavell RA; Kantor FS
    J Immunol; 1996 Dec; 157(12):5496-502. PubMed ID: 8955199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula.
    Nassal M; Skamel C; Kratz PA; Wallich R; Stehle T; Simon MM
    Eur J Immunol; 2005 Feb; 35(2):655-65. PubMed ID: 15668917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi.
    Langermann S; Palaszynski S; Sadziene A; Stover CK; Koenig S
    Nature; 1994 Dec; 372(6506):552-5. PubMed ID: 7990928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lyme borreliosis--vaccines in the "pipeline"].
    Kramer M
    MMW Fortschr Med; 1999 Jun; 141(25):52-3. PubMed ID: 10897909
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis.
    Fawcett PT; Rose CD; Budd SM; Gibney KM
    Clin Diagn Lab Immunol; 2001 Jan; 8(1):79-84. PubMed ID: 11139199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA.
    Ding W; Huang X; Yang X; Dunn JJ; Luft BJ; Koide S; Lawson CL
    J Mol Biol; 2000 Oct; 302(5):1153-64. PubMed ID: 11183781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization against Lyme disease--an important first step.
    Steigbigel RT; Benach JL
    N Engl J Med; 1998 Jul; 339(4):263-4. PubMed ID: 9673306
    [No Abstract]   [Full Text] [Related]  

  • 20. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA.
    Koide S; Yang X; Huang X; Dunn JJ; Luft BJ
    J Mol Biol; 2005 Jul; 350(2):290-9. PubMed ID: 15935380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.